[ad_1] Honored to present at the @RetinaWCongress panel discussion on “New Pathways in Retinal Diseases”. @RWCRetina #eyes #retina #macula #ophthalmology #biotech #biotechnology #medicine #clinicalresearch #clinicaltrials #drugdevelopment #suprachoroidal #xipere https://t.co/a5X8MEIMHo [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @TheLens_oph: Predicting the future with OCT biomarkers for macular edema in non-infectious #uveitis. Read more on @ThomasCiullaMD’s lat…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @ThomasCiullaMD: Congrats to colleagues & partners with numerous #arvo2022 presentations on #suprachoroidal delivery, with the SCS Micr… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @Healio_OSN: Two phase 3 studies showed that suprachoroidal triamcinolone acetonide injections led to significant improvement in visual… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
At #arvo2022, with colleagues who worked at Spark prior to #Luxturna launch, which involved novel functional vision #endpoints, complex #genetictesting paradigms, new administration procedures at treatment centers, & unique reimbursement pathways associated with #genetherapy https://t.co/MMo8oZeVD5
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] Congrats to colleagues & partners with numerous #arvo2022 presentations on #suprachoroidal delivery, with the SCS Microinjector. In addition to FDA-approved #Xipere, 6 clinical trials globally are assessing 4 different investigational therapies, using the SCS Microinjector.#eye https://t.co/TFshyatTTH [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @eyetubenet: Join Drs. Sunil Srivastava, Dilraj Grewal, and Steven Yeh for this #CME Series: Harnessing the Suprachoroidal Space for the… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.